Potency Assay Issues Delayed US FDA Approval Of Mesoblast’s Ryoncil For Years

 
• By Sue Sutter

The company’s failure to show its potency assays measured attributes directly related to the mesenchymal stromal cell product’s therapeutic effect highlights the importance of a robust CMC program for complex cell therapies.

Ryoncil CMC story
Mesoblast's potency assays drew the FDA's attention. (Nancy Pham)

More from Drug Review Profiles

More from Advanced Technologies